Magic

[MWM]

$ONVO An Open Letter to Organovo Shareholders: Organovo Founder Sees Continued Success in Bioprinting

Keith Murphy, founder, former CEO and Chairman Emeritus of Organovo, says bioprinting and similar technologies are going strong and still growing
Companies in the space are finding support from institutional capital sources, and those with tools and service business models are achieving 40%+ per year revenue growth
Viscient Biosciences, Mr. Murphy’s current company, has already crossed a major milestone in the application of bioprinting to NASH drug discovery
Viscient incorporates into bioprinting additional cutting edge techniques, including single cell sequencing and bioinformatics tools
Major investment funds have expressed support for Viscient’s approach
January 07, 2020 08:00 AM Eastern Standard Time

https://www.businesswire.com/news/home/20200107005367/en/Open-Letter-Organovo-Shareholders-Organovo-Founder-Sees